ATE415972T1 - Präventiver oder therapeutischer wirkstoff gegen glaukom - Google Patents

Präventiver oder therapeutischer wirkstoff gegen glaukom

Info

Publication number
ATE415972T1
ATE415972T1 AT05819681T AT05819681T ATE415972T1 AT E415972 T1 ATE415972 T1 AT E415972T1 AT 05819681 T AT05819681 T AT 05819681T AT 05819681 T AT05819681 T AT 05819681T AT E415972 T1 ATE415972 T1 AT E415972T1
Authority
AT
Austria
Prior art keywords
therapeutic agent
glaucoma
preventive
agent against
salt
Prior art date
Application number
AT05819681T
Other languages
English (en)
Inventor
Makoto Kanebako
Masatoshi Takahashi
Ken Mizuno
Shin Sugimoto
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Application granted granted Critical
Publication of ATE415972T1 publication Critical patent/ATE415972T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05819681T 2004-12-23 2005-12-22 Präventiver oder therapeutischer wirkstoff gegen glaukom ATE415972T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63811804P 2004-12-23 2004-12-23

Publications (1)

Publication Number Publication Date
ATE415972T1 true ATE415972T1 (de) 2008-12-15

Family

ID=36601805

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05819681T ATE415972T1 (de) 2004-12-23 2005-12-22 Präventiver oder therapeutischer wirkstoff gegen glaukom

Country Status (23)

Country Link
EP (1) EP1818059B1 (de)
JP (1) JP4099201B2 (de)
KR (1) KR101286813B1 (de)
CN (1) CN101087613B (de)
AT (1) ATE415972T1 (de)
AU (1) AU2005320085B2 (de)
BR (1) BRPI0519007A2 (de)
CA (1) CA2585372A1 (de)
CY (1) CY1108651T1 (de)
DE (1) DE602005011476D1 (de)
DK (1) DK1818059T3 (de)
EA (1) EA011085B1 (de)
ES (1) ES2317338T3 (de)
MX (1) MX2007007614A (de)
MY (1) MY138811A (de)
NO (1) NO20072187L (de)
NZ (1) NZ555137A (de)
PL (1) PL1818059T3 (de)
PT (1) PT1818059E (de)
SI (1) SI1818059T1 (de)
TW (1) TWI367098B (de)
WO (1) WO2006068208A1 (de)
ZA (1) ZA200704874B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007879A1 (ja) * 2005-07-14 2007-01-18 Sharp Kabushiki Kaisha 表示素子、及びこれを用いた電気機器
CN102099037A (zh) 2008-07-25 2011-06-15 旭化成制药株式会社 含有磺酰胺化合物的稳定的水溶液组合物
CN103338772A (zh) * 2011-02-04 2013-10-02 兴和株式会社 用于预防或治疗青光眼的药物疗法
EA026904B1 (ru) * 2012-11-23 2017-05-31 Игорь Михайлович Юхт Способ количественного определения полигексаметиленбигуанидина (пгмб) гидрохлорида в составах для приготовления жидких лекарственных средств для лечения заболеваний глаз и носа (2 варианта)
US20160339018A1 (en) * 2013-04-24 2016-11-24 Kyushu University, National University Corporation Therapeutic agent for ocular fundus disease
MX377963B (es) 2014-09-25 2025-03-10 Kowa Co Composición acuosa.
MY179721A (en) * 2014-09-25 2020-11-11 Kowa Co Pharmaceutical product
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法
MY178881A (en) 2014-12-12 2020-10-21 Kowa Co Novel aqueous composition
KR20160108121A (ko) 2015-03-06 2016-09-19 코와 가부시키가이샤 수성 조성물
JP2018118905A (ja) * 2015-04-27 2018-08-02 恵 本庄 白内障術後合併症の予防治療剤
CN106310285A (zh) * 2015-06-15 2017-01-11 江苏吉贝尔药业股份有限公司 一种新的盐酸利舒地尔滴眼液及其制备方法
JP6886322B2 (ja) * 2016-03-25 2021-06-16 興和株式会社 眼科用組成物
CN107164328A (zh) * 2017-06-30 2017-09-15 太仓卡斯特姆新材料有限公司 一种高稳定性mcf‑7乳腺癌细胞的复苏方法
CA3086457A1 (en) 2017-12-21 2019-06-27 Santen Pharmaceutical Co., Ltd. Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
JP2020193174A (ja) * 2019-05-29 2020-12-03 興和株式会社 水性組成物
EP4274578A1 (de) 2021-01-11 2023-11-15 Incyte Corporation Kombinationstherapie mit jak-pfad-inhibitor und rock-inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9401108D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
DE19512639A1 (de) * 1995-04-05 1996-10-10 Merck Patent Gmbh Benzonitrile und -fluoride
PT868186E (pt) * 1995-12-21 2005-05-31 Alcon Lab Inc Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular
JPH10310576A (ja) * 1997-03-10 1998-11-24 Hiroyoshi Hidaka イソキノリンスルフォンアミド誘導体及びこれを有効成分とする医薬
EP0977756A1 (de) * 1997-04-25 2000-02-09 Pfizer Limited Pyrazolopyrimidinone, die den typ 5 der cyclischen guanosin 3',5'-monophosphat phospodiesterase (cgmp pde5) hemmen, zur behandlung von sexuellen funktionsstörungen
FR2777189B1 (fr) 1998-04-09 2001-04-06 Chauvin Lab Sa Composition ophtalmique comprenant un beta-bloquant
CA2327276A1 (en) * 1998-04-23 1999-10-28 Hiroshi Muramatsu Isoquinolinesulfonamide derivatives and drugs containing the same as the active ingredient
JP4212149B2 (ja) * 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
AU5198199A (en) 1998-08-17 2000-03-06 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
OA11665A (en) * 1998-10-22 2004-12-08 Neurosearch As Substituted phenyl derivatives, their preparation and use.

Also Published As

Publication number Publication date
HK1113312A1 (zh) 2008-10-03
KR20070090897A (ko) 2007-09-06
EP1818059B1 (de) 2008-12-03
AU2005320085A1 (en) 2006-06-29
WO2006068208A1 (ja) 2006-06-29
PT1818059E (pt) 2008-12-31
KR101286813B1 (ko) 2013-07-17
CY1108651T1 (el) 2014-04-09
BRPI0519007A2 (pt) 2008-12-23
ZA200704874B (en) 2008-08-27
DE602005011476D1 (de) 2009-01-15
JPWO2006068208A1 (ja) 2008-06-12
JP4099201B2 (ja) 2008-06-11
EP1818059A1 (de) 2007-08-15
TW200628160A (en) 2006-08-16
EA200701134A1 (ru) 2007-10-26
SI1818059T1 (sl) 2009-04-30
EA011085B1 (ru) 2008-12-30
ES2317338T3 (es) 2009-04-16
PL1818059T3 (pl) 2009-05-29
MX2007007614A (es) 2007-08-15
DK1818059T3 (da) 2009-03-16
MY138811A (en) 2009-07-31
CN101087613A (zh) 2007-12-12
TWI367098B (en) 2012-07-01
EP1818059A4 (de) 2007-12-26
NO20072187L (no) 2007-07-13
NZ555137A (en) 2009-10-30
CN101087613B (zh) 2010-08-18
AU2005320085B2 (en) 2010-07-29
CA2585372A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
NO20072187L (no) Preventivt eller terapeutisk middel for glaucom
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
IL160420A0 (en) Treating or preventing diabetes with cannabidiol
ATE480240T1 (de) Zusammensetzung enthaltend latanoprost und behandlungsmethode von erhöhtem augeninnendruck und glaukom
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2008039397A3 (en) Method and intra-sclera implant for treatment of glaucoma and presbyopia
WO2007076367A3 (en) Rnai-mediated inhibition of rho kinase for treatment of ocular hypertension / glaucoma
WO2004069181A3 (en) Composition for the treatment of intraocular pressure
SG171602A1 (en) Use of antisecretory factors for treating intraocular hypertension
WO2003005941A3 (de) Insert zur behandlung des trockenen auges
NO20060114L (no) Naftylenderivater som cytokrom P450-inhibitorer
WO2007127711A3 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
BRPI0510245A (pt) estatinas para o tratamento de hipertensão ocular e glaucoma
MX2008015976A (es) Tratamiento topico para enfermedades de superficie ocular.
EP1482922A4 (de) Mittel für die corneale oder intrastromale verabreichung zur behandlung oder prävention von erkrankungen des auges
EP1752158A4 (de) Pacap und sein derivat enthaltender korneaneuritogenese-promoter
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
TW200806284A (en) Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
WO2002060339A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004087051A3 (en) Ophthalmic compositions for treating ocular hypertension
RU2007104148A (ru) Способ коррекции зрения после хирургических операций, выполненных на роговой оболочке глаза

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1818059

Country of ref document: EP